ARTV Stock Forecast & Price Target

Artiva Biotherapeutics is positioned favorably because AlloNK is showing encouraging early efficacy in Sjögren's disease, an underappreciated large indication with significant unmet need, while 11 patients now have ~6 months of follow-up and the broader 73-patient dataset spanning RA, SSc, and myositis has shown no ICANS, CRS, or GvHD. The data are especially compelling because the -3.5-point ESSPRI improvement exceeds the clinically meaningful threshold and the ~1.1 mL/min stimulated salivary flow crossed into the normal range, both of which compare favorably with competitors and support differentiated disease-modifying potential. With favorable safety that could fit community use and a large SjD market that lacks approved therapies, the company’s off-the-shelf NK platform appears well positioned for further development.

Artiva Biotherapeutics is viewed negatively because it discontinued its lead AlloNK program after two patient deaths, including one case of leukoencephalopathy likely attributable to fludarabine, while longer-term data also suggested insufficient response durability. The halt of Phase II and Phase III enrollment, along with a planned ~94% workforce reduction and withdrawal of data presentations, removes the company’s primary value driver and signals a severe deterioration in its development outlook. Although preliminary cash as of Sep. 30, 2026 was $319.1MM, the need for further funding, heavy severance and termination costs, early-stage pipeline risk, and intense competition leave limited near-term fundamentals to support the stock.